Thanks to our close relationship with vendors and manufacturers, we have the unique capability to find niche products and hard to find medicines. You can rely on us for getting the newest approved products in the market and those not yet available in some countries. Our range of products is so wide, you won’t need to look for other suppliers.
with a wide clients’ base made of hospitals, private clinics, pharmacies and distributors, we have developed a deep knowledge of what the needs, constraints and priorities are for each or our client. That is why we understand your urgency and we can fully meet your demands with the highest standards of service.
Our stringent operating procedures guarantee every step of handling, storage and distribution of all medicinal products.
When you contact us in Elixi, you know you are getting the best customer service: our dedicated people will offer you quick responses, personalised approach and bespoke solutions. Our approach is not to follow only standard procedures but taking care of every specific detail and taking to heart every request and individual issues.
The FDA has approved Qinlock (ripretinib) tablets as the first new drug specifically approved as a fourth-line treatment for advanced
Novartis has announced that the US Food and Drug Administration (FDA) approved Tabrecta (capmatinib), an oral MET inhibitor for adult patients
MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate is a new Vaccine for the prevention of invasive meningococcal disease in persons
As part of Project Orbis, the U.S. Food and Drug Administration has approved Tukysa (tucatinib) in combination with chemotherapy (trastuzumab and
The FDA has approved Koselugo (selumetinib) for the treatment of pediatric patients, 2 years of age and older, with neurofibromatosis
The FDA has approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple
Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040
